SecBot SecBot
SECBOTREPLAY Home › Report › OLMA

OLMA · Olema Oncology released preclinical data showing palazestrant fully…

Olema Oncology · PRESS-RELEASE filed Apr 17, 2026 at 16:01 ET

At the news

MIXEDIMPACT 5/10

PRESS-RELEASE filed Apr 17, 2026 at 16:01 ET

Olema Oncology released preclinical data showing palazestrant fully recruits the NCoR1 corepressor for complete estrogen receptor antagonism, and demonstrates synergistic anti-tumor activity when combined with OP-3136 in ER+/HER2- breast cancer models. The data support ongoing Phase 3 trials of palazestrant and the development of OP-3136 in combination therapy, though no clinical efficacy results were reported.

  • Preclinical data show palazestrant recruits NCoR1, enabling complete antagonism of estrogen receptor signaling in ER+/HER2- breast cancer models.
  • Combination of palazestrant and OP-3136 shows synergistic anti-tumor activity by suppressing cell-cycle and ER-driven oncogenic pathways.
  • Palazestrant is in two ongoing Phase 3 trials (OPERA-01 and OPERA-02); top-line data from OPERA-01 expected in fall 2026.
  • OP-3136, a KAT6 inhibitor, is in a Phase 1 trial with patient enrollment ongoing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access